About Pivotal Therapeutics
Pivotal Therapeutics is a company based in Vaughan (Canada) founded in 2010 by George Jackowski and Rachelle MacSweeney. Pivotal Therapeutics operates in a competitive market with competitors including Portola Pharma, MyoKardia, Cellino, Arrakis Therapeutics and Tenaya Therapeutics, among others.
- Headquarter Vaughan, Canada
- Founders George Jackowski, Rachelle MacSweeney
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$7.7 M (USD), Debt – Conventional
Mar 04, 2014
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Pivotal Therapeutics
Investments & Acquisitions by Pivotal Therapeutics
Investment portfolio details for Pivotal Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Pivotal Therapeutics
Detailed financials for Pivotal Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pivotal Therapeutics Comparisons
Peer comparison for Pivotal Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Pivotal Therapeutics
Pivotal Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Portola Pharma, MyoKardia, Cellino, Arrakis Therapeutics and Tenaya Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for cardiovascular and autoimmune diseases are developed.
|
|
| Locked | Locked | Locked |
Specialized drugs are developed for genetic heart diseases.
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
Provider of tools for the analysis of RNA structures
|
|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| Locked | Locked | Locked |
Innovative pharmaceuticals for cardiovascular and metabolic diseases are developed.
|
Detailed competitors of Pivotal Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pivotal Therapeutics
Complete news archive for Pivotal Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pivotal Therapeutics
Pivotal Therapeutics was founded in 2010 and raised its 1st funding round 4 years after it was founded.
Pivotal Therapeutics is headquartered in Vaughan, Canada. It is registered at Vaughan, Ontario, Canada.
Rachelle MacSweeney is the current CEO of Pivotal Therapeutics. They have also founded this company.
Pivotal Therapeutics is a Canadian, commercial-stage biopharma developing highly-purified prescription Omega 3 Therapy for CVD. In Feb 2016, it announced US patent for stabilization of vulnerable plaque using a combination of statin and Omega 3 fatty acids. The company has one prescription product and 2 OTC products. The prescription product is VASCAZEN, indicated for Omega-3 Deficiency in cardiovascular patients. The product was clinically shown to correct an Omega-3 Deficiency in CVD Patients, with an associated 48 reduction in triglycerides and a rise in HDL-C without negative impact on the LDL-C lipid profile in the 8-week treatment period. The 2 OTC Products are OMAZEN and BENEFISHIAL.
Pivotal Therapeutics's top competitors include Tenaya Therapeutics, Cellino and MyoKardia.